Latest news with #Neurogen
Yahoo
21-05-2025
- Business
- Yahoo
Neurogen Biomarking Announces Partnership with Aranscia
Aranscia Diagnostic Laboratory and Technology Solutions Support Neurogen's Innovative Platform for the Early Detection of Mild Cognitive Impairment (MCI) and Alzheimer's Dementia CHICAGO and HOUSTON, May 21, 2025 /PRNewswire/ -- Neurogen Biomarking, the world's first ecosystem for memory loss with end-to-end patient support, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced a partnership in which Aranscia's technical and laboratory resources will help to deliver clinical insights and HIPAA-compliant connectivity for the Neurogen Biomarking ecosystem. Under this partnership, AccessDx Laboratory, an Aranscia company, will provide Neurogen with technical, operational, and analytical support resources for its blood-based biomarker test that measures phosphorylated tau (p-tau) 217, a specific marker for Alzheimer's disease pathology. AccessDx Laboratory is a CAP-accredited, CLIA-certified, NYSDOH-approved diagnostic laboratory focused on both the development and scaling of novel diagnostic programs. In addition, 2bPrecise, another Aranscia company, will provide Neurogen with software-based, EMR-agnostic clinical workflow utilities that help to securely integrate Neurogen's diagnostic results and programmatic insights across the Neurogen ecosystem and within a wide range of clinical care settings. 2bPrecise's HIPAA-compliant software solutions currently support thousands of discrete client groups, including leading health systems, municipalities, ACOs, and multi-provider organizations. "Neurogen's driving force is to solve the issue of delayed detection and ultimately diagnosis by empowering patients in a scientifically and clinically controlled ecosystem while also guiding them every step of the way in their brain health journey," said Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking. "Aranscia's proven experience in supporting a wide range of complex diagnostic and clinical workflows, combined with their expertise in enabling innovative and secure end-to-end personalized diagnostic programs, makes them the ideal partner to help us both achieve our objectives and position for scale." Neurogen's platform is the first patient-initiated system designed to shift the paradigm of early detection of Alzheimer's disease (AD) through improved access to innovative blood biomarker testing and AI-enhanced digital and cognitive assessments. Board-certified neurologists will support eligible Neurogen patients every step of the way via telehealth, providing follow-up care if indicated and accelerating access to expert cognitive care - delivered in weeks rather than the months-long wait times typically seen in traditional neurology care. "We're proud to partner with Neurogen on its mission to accelerate early detection and interventionist care in the fight against Alzheimer's disease, which has become all too personal for millions of Americans and their families," said Bryon Cipriani, CEO of Aranscia. "This partnership builds upon the foundational efforts of AccessDx Laboratory and 2bPrecise in helping to democratize access to personalized and precision care for all, and in ways that proactively and positively impacts the lives of the patients we help to serve." Aranscia joins Neurogen's collaborators Linus Health, which is providing the cutting-edge digital cognitive assessments for patients with memory concerns on the Neurogen Biomarking platform; Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection; and NeuroX, a venture of American TelePhysicians, to provide virtual neurology services that help guide the patient journey on its brain health care ecosystem. The platform will be widely available in mid-2025 for anyone with eligible memory and thinking concerns. Approximately 7 million Americans aged 65 and older were living with Alzheimer's dementia in 2024. It is estimated that 40% of Americans age 65+ experience memory impairment, affecting around 16 million people. Only 8% of Americans living with mild cognitive impairment receive a diagnosis, leaving 92% undiagnosed. The process of developing Alzheimer's disease is slow, with 15-20 years before the onset of Mild Cognitive Impairment (MCI). MCI precedes Alzheimer's disease by many years. About Neurogen BiomarkingNeurogen Biomarking is dedicated to supporting early detection of Alzheimer's disease and Mild Cognitive Impairment. Founded by award-winning neurologist, Dr. Rany Aburashed and guided by world-renowned brain health experts, Neurogen is on a mission to empower anyone with thinking and memory concerns with the tools, education, and motivation needed to access advanced, personalized care of patients with Alzheimer's disease – and a future with more in it. To learn more visit or follow us on LinkedIn. About Aranscia Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia's portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more information, please visit Media Contacts:Neurogen Biomarking395551@ Aranscia 395551@ View original content to download multimedia: SOURCE Aranscia Sign in to access your portfolio
Yahoo
09-04-2025
- Business
- Yahoo
KRTL Holding Announces Acquisition of Neurogen Brain Balancing, LLC – A Strategic Merger Accelerating Global Neurotech and Mental Wellness Expansion
Lakewood, CO, April 09, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE KRTL Holding Announces Acquisition of Neurogen Brain Balancing, LLC – A Strategic Merger Accelerating Global Neurotech and Mental Wellness Expansion KRTL Holding Group Inc., a diversified international enterprise focused on biotech innovation, regulatory infrastructure, and strategic investment, is pleased to announce the acquisition of Neurogen Brain Balancing, LLC, a California-based neurotechnology company known for its advanced brain balancing therapies and personalized cognitive optimization systems. This transformative acquisition expands KRTL's presence in the mental wellness space and enhances its position at the intersection of neuroscience, biotechnology, and global healthcare. This acquisition establishes Neurogen as a subsidiary of KRTL Holding Group Inc., representing a pivotal step in the company's broader strategy to integrate advanced neurotechnology into its ecosystem and support the growth of scalable mental health solutions. Under the terms of the transaction, KRTL has acquired 100% of Neurogen's equity through a stock-based structure that also includes a collaborative profit-sharing agreement. Additional elements of the consideration include KRTL's commitment to support Neurogen's entry into new markets and provide FDA-related services to enhance regulatory pathways and strategic growth alignment between the two companies. 'We are thrilled to welcome Neurogen into the KRTL Holding Group family,' said Cesar Herrera, CEO of KRTL Holding Group. 'In today's rapidly evolving global environment, diversification is not just a strategy—it's a necessity. By bringing Neurogen into our ecosystem, we strengthen our ability to remain agile, resilient, and forward-thinking across multiple sectors. Their innovative work is a natural fit for our mission to invest in businesses that shape the future.' Neurogen's proprietary neurotechnology utilizes advanced neuromodulation protocols that support applications ranging from cognitive performance enhancement to stress reduction and post-trauma recovery. The platform is particularly well-positioned to address critical gaps in the continuation of care for patients seeking alternative therapies. By offering non-opioid, non-invasive treatment options with simplified access, the technology aligns with broader healthcare priorities around expanding safe, effective, and accessible behavioral and neurological health interventions. "This acquisition marks an exciting new chapter for Neurogen. Joining forces with KRTL Holding Group enables us to accelerate our mission of transforming mental health treatment through cutting-edge neurotechnology. With KRTL's global infrastructure and regulatory expertise, we're well-positioned to scale our solutions and reach underserved communities worldwide. Together, we aim to expand access to non-invasive, personalized brain health therapies—advancing a new global standard for neurological wellness," said Gregory Gillispie, President of NeuroGen. "The guidance and infrastructure offered by KRTL enhance our ability to grow responsibly while continuing to focus on improving lives through brain balance." Strategic Integration and Global Expansion Framework As part of the integration, Neurogen is being incorporated into KRTL's operational and regulatory infrastructure. These efforts, which include brand alignment across digital channels and investor communications, financial system harmonization, and scalable operational planning, are underway and being informed by both internal leadership and third-party advisors. KRTL's internal systems, including its Quality Management System (QMS) and Enterprise Resource Planning (ERP) infrastructure, are currently under expert review. This assessment is aimed at identifying the most effective enhancements to support joint business capabilities and long-term performance. Further coordination is focused on regulatory and clinical alignment, including FDA-compliant trial design and support for international submissions. Neurogen is also positioned to participate in real-world data research through its connection with Centro de Investigaciones Químicas - CIQ S.R.L in Bolivia, contributing to global product validation efforts. As the collaboration evolves, KRTL intends to issue follow-up announcements that will provide added clarity, updates on integration progress, and forward-looking insights. About KRTL Holding Group Inc. KRTL Holding Group Inc. is a dynamic holding company operating through its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. These subsidiaries specialize in biopharmaceutical innovation, international trade, and compliance-driven healthcare advancements. By leveraging strategic mergers, acquisitions, and joint ventures, KRTL Holding Group continues to push the boundaries of scientific research, regulatory compliance, and global business solutions. Additional information on KRTL is available online at and and This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, anticipated business developments, regulatory advancements, and strategic growth plans. Such forward-looking statements involve known and unknown risks that may cause actual results to differ materially from those expressed or implied. KRTL Holding Group assumes no obligation to update or revise forward-looking statements, except as required by law. Any updates will be made in accordance with applicable SEC regulations and disclosure obligations. Readers are cautioned not to place undue reliance on forward-looking statements. CONTACT: info@ info@ info@ in to access your portfolio
